24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
SUNITCAP 25MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | SUNITCAP 25MG |
|---|---|
| Composition | Sunitinib Malate Capsules 25mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
SUNITCAP 25MG (Sunitinib Malate Capsules 25mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
SUNITCAP 25 MG (Sunitinib Malate Capsules 25 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 25 mg, a potent Tyrosine Kinase Inhibitor (TKI) used for the treatment of various advanced cancers. It works by blocking specific proteins that play a critical role in cancer cell growth, tumor progression, and the development of blood vessels that supply nutrients to tumors.
Sunitinib is widely recognized in modern oncology for its targeted mechanism of action. By inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, it helps slow the progression of cancer and supports long-term disease control.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Sunitinib specifically targets molecular pathways associated with cancer development. This targeted approach has made it an important treatment option for several advanced and metastatic cancers.
SUNITCAP 25 MG is commonly prescribed for:
The 25 mg strength is often used for individualized treatment regimens, dose modifications, maintenance therapy, or patients requiring adjusted doses based on treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid monitoring, and regular medical evaluations.
Due to its proven effectiveness in managing several advanced cancers, SUNITCAP 25 MG remains an important medicine in contemporary oncology practice.
SUNITCAP 25 MG (Sunitinib Malate Capsules 25 mg) is primarily used in the treatment and management of specific advanced cancers.
The medicine is commonly prescribed for advanced and metastatic kidney cancer.
Sunitinib may be used in patients whose disease has progressed despite previous treatment.
The medicine helps manage certain advanced neuroendocrine tumors of the pancreas.
Doctors may recommend Sunitinib to help slow tumor growth and disease progression.
The medicine is frequently incorporated into personalized cancer treatment plans.
Sunitinib supports prolonged disease stabilization and treatment response.
The 25 mg strength allows flexible dosing based on patient-specific requirements.
Sunitinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
SUNITCAP works by:
This targeted mechanism helps control cancer growth and spread more effectively.
Like all medicines, SUNITCAP 25 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported during treatment.
Elevated blood pressure may occur and requires monitoring.
Digestive disturbances may develop during therapy.
Some patients may experience nausea.
Reduced appetite may affect nutritional intake.
Inflammation or ulcers in the mouth may occur.
Changes in skin color or pigmentation may develop.
Redness, swelling, and discomfort of the hands and feet may occur.
The medicine may alter thyroid hormone levels.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of SUNITCAP 25 MG (Sunitinib Malate Capsules 25 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Cancer severity and progression influence treatment planning.
Liver, kidney, heart, and thyroid function may affect dosage decisions.
Doctors may modify therapy according to effectiveness and tolerance.
Potential drug interactions may require dosage adjustments.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of advanced kidney cancer, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
Sunitinib Malate is a targeted anticancer medicine that blocks proteins involved in cancer growth and blood vessel formation.
No. It is a targeted therapy known as a tyrosine kinase inhibitor and works differently from conventional chemotherapy.
The 25 mg strength is commonly used for dose adjustments, individualized treatment plans, or maintenance therapy.
Yes. High blood pressure is a common side effect and requires regular monitoring.
Yes. Thyroid hormone changes may occur and should be monitored periodically.
Yes. Blood pressure checks, blood tests, thyroid assessments, and clinical evaluations are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.